Cristos Ifantides, MD
Ophthalmology · Denver, CONPI 1821356676
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $230,731 of the $342,946 with a category attached, or 67.3%. 26 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 56.4% of the total. 2025 is the largest year on record at $198,372, more than ten times the $6,904 reported in 2019. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 377 payments — averaging $909.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$193K
- Alcon Research LLC$43K
- Alcon$39K
- AbbVie$16K
- Johnson & Johnson Surgical Vision, Inc.$12K
- Bausch & Lomb Americas Inc.$10K
- plus $30K from 20 others
Across 11 payments — averaging $97,375 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$1.1M
- Bausch & Lomb Americas Inc.$17K
- Johnson & Johnson Surgical Vision, Inc.$3K
What the payments were for
- Consulting fees$230,73167%
- Speaking & faculty fees$88,55126%
- Travel & lodging$8,4422%
- Food & beverage$15,1824%
- Education$210%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 38 | $193,419 |
| Alcon Research LLC | 18 | $43,019 |
| Alcon | 85 | $38,870 |
| AbbVie(2 entities) | 75 | $15,658 |
| Johnson & Johnson Surgical Vision, Inc. | 21 | $11,779 |
| Bausch & Lomb Americas Inc. | 38 | $9,851 |
| NEW World Medical,inc. | 8 | $6,325 |
| Sight Sciences, Inc. | 14 | $5,934 |
| Carl Zeiss Meditec USA, Inc. | 8 | $4,694 |
| Dompe US, Inc. | 13 | $3,538 |
| Lensar, Inc. | 10 | $3,458 |
| Carl Zeiss Meditec, Inc. | 6 | $3,133 |
| Glaukos Corporation | 16 | $1,099 |
| Beaver-visitec International, Inc. | 1 | $500 |
| Sun Pharmaceutical Industries Inc. | 5 | $426 |
| Microsurgical Technology, Inc. | 1 | $330 |
| Carl Zeiss Meditec Cataract Technology Inc. | 6 | $253 |
| Ocular Therapeutix, Inc. | 3 | $206 |
| Dutch Ophthalmic, USA | 2 | $169 |
| Rayner Intraocular Lenses Limited | 3 | $99 |
| Kala Pharmaceuticals, Inc. | 1 | $46 |
| Novartis | 1 | $42 |
| Omeros Corporation | 1 | $34 |
| Rxsight Inc | 1 | $26 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$41,872
- Tecnis IOL$33,450
- XDEMVY$33,085
- AcrySof IQ PanOptix UV IOL$18,561
- AcrySof IQ VIVITY$10,224
- Centurion$8,500
- Ahmed Glaucoma Valve$6,180
- Kahook Dual Blade$6,180
- VUITY$6,150
- IOLMaster 700$5,710
- OMNI(R) SURGICAL SYSTEM (US)$5,654
- VERACITY SURGICAL$4,149
- QUATERA 700$4,000
- enVista MX60 IOL$3,966
- DURYSTA$3,868
- Oxervate$3,394
- LENSAR LASER SYSTEM$3,357
- MIEBO$3,075
- XIIDRA$2,950
- FORUM$2,700
How this compares
$342,946 in reported general payments places this provider in the 95th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 23 | $42,677 |
| RestasisCyclosporine | 28 | $30,129 |
| LumiganBimatoprost | 24 | $13,204 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 41 | $11,024 |
| Alphagan PBrimonidine Tartrate | 12 | $7,044 |
| Latanoprost | 478 | $5,530 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 33 | $4,475 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 195 | $3,945 |
| Ketorolac Tromethamine | 134 | $3,685 |
| Travoprost | 23 | $3,535 |
| Timolol Maleate | 194 | $3,328 |
| Prednisolone Acetate | 91 | $3,256 |
| Brimonidine Tartrate | 164 | $964 |
| ValacyclovirValacyclovir Hcl | 23 | $940 |
| Dorzolamide Hcl | 47 | $901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $15,658 | $50,37764 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $193,419 | $42,67723 claims |
| AlconSimbrinza | $38,870 | $11,02441 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Denver
- Mark DaceyDenver$370K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
- Kingsley OkaforDenver$62K
- Curtis HagedornDenver$25K
- Michael SolomonDenver$12K
- Peter HovlandDenver$10K
- Matthew KrugerDenver$8K
- Stuart LewisDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.